INT26273

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 7.64
Pain Relevance 3.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (RYR1) transmembrane transport (RYR1) cytoplasm (RYR1)
Anatomy Link Frequency
CCO 4
head 1
reticulum 1
Body 1
RYR1 (Homo sapiens)
RYR1 - D4899Q (1)
Pain Link Frequency Relevance Heat
Intracerebroventricular 4 99.14 Very High Very High Very High
tolerance 12 98.34 Very High Very High Very High
Morphine 18 98.14 Very High Very High Very High
Antinociceptive 4 96.32 Very High Very High Very High
Potency 19 91.64 High High
antinociception 6 88.80 High High
addiction 63 88.12 High High
tail-flick 2 87.28 High High
halothane 30 82.40 Quite High
headache 3 76.52 Quite High
Disease Link Frequency Relevance Heat
Syndrome 44 99.68 Very High Very High Very High
Stroke 31 99.52 Very High Very High Very High
Malignant Hyperthermia 343 98.96 Very High Very High Very High
Targeted Disruption 6 98.80 Very High Very High Very High
Rhabdomyolysis 28 98.20 Very High Very High Very High
Hyperkalemia 28 97.44 Very High Very High Very High
Arrhythmia Under Development 6 92.80 High High
Intellectual Impairment 3 91.96 High High
Coronary Artery Disease 4 91.52 High High
Optic Atrophy 3 91.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In most cases, the syndrome is caused by a defect in the ryanodine receptor.
Negative_regulation (defect) of ryanodine receptor associated with syndrome
1) Confidence 0.43 Published 2007 Journal Orphanet J Rare Dis Section Abstract Doc Link PMC1867813 Disease Relevance 1.58 Pain Relevance 0.07
As lymphoblastoid cell lines do not express the dihydropyridine receptor, they could also effectively be used to functionally test RYR1 mutations as well as to eliminate RYR1 as a causative factor in MH individuals who do not show linkage to RYR1.
Negative_regulation (eliminate) of RYR1 associated with malignant hyperthermia
2) Confidence 0.43 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1867813 Disease Relevance 0.25 Pain Relevance 0.03
When the CCO was switched off, no more arrhythmias were observed.
Negative_regulation (switched) of CCO in CCO
3) Confidence 0.36 Published 2009 Journal Lab. Anim. Section Abstract Doc Link 19237458 Disease Relevance 0.36 Pain Relevance 0
The experimentally observed decreased selectivity of Ca2+ over K+ in RyR1-D4899Q can be rationalized from our simulations.
Negative_regulation (decreased) of RyR1-D4899Q (D4899Q)
4) Confidence 0.27 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0 Pain Relevance 0
Scattered fibers had no cytochrome c oxidase (CCO) activity representing focal CCO deficiency.
Negative_regulation (deficiency) of CCO in CCO
5) Confidence 0.15 Published 1989 Journal Rinsho Shinkeigaku Section Abstract Doc Link 2553313 Disease Relevance 1.46 Pain Relevance 0.08
Scattered fibers had no cytochrome c oxidase (CCO) activity representing focal CCO deficiency.
Negative_regulation (deficiency) of CCO in CCO
6) Confidence 0.15 Published 1989 Journal Rinsho Shinkeigaku Section Abstract Doc Link 2553313 Disease Relevance 1.47 Pain Relevance 0.08
The progression of the MELAS was probably in parallel with the decrease in CCO activity.
Negative_regulation (decrease) of CCO in CCO
7) Confidence 0.13 Published 1989 Journal Rinsho Shinkeigaku Section Abstract Doc Link 2553313 Disease Relevance 0.99 Pain Relevance 0
The specific action of tetracaine to inhibit Ca2+ release channel-ryanodine receptor activity may in part counterbalance the nonspecific action, resulting in moderate myotoxicity.


Negative_regulation (inhibit) of channel-ryanodine receptor
8) Confidence 0.10 Published 1999 Journal Anesthesiology Section Body Doc Link 10078686 Disease Relevance 0 Pain Relevance 0
Moreover, a significant reduction in ryanodine receptor binding was also observed in primary IOOA.
Negative_regulation (reduction) of ryanodine receptor
9) Confidence 0.05 Published 2006 Journal Yonsei Medical Journal Section Body Doc Link PMC2687630 Disease Relevance 0.09 Pain Relevance 0
In the present study, the amount and rate of Ca2+ uptake was determined when the ryanodine receptor was completely blocked.
Negative_regulation (blocked) of ryanodine receptor
10) Confidence 0.05 Published 2006 Journal Yonsei Medical Journal Section Body Doc Link PMC2687630 Disease Relevance 0.24 Pain Relevance 0
After blocking ryanodine receptor in the sarcoplasmic reticulum, the same amounts of whole homogenate and non-labeled ryanodine were placed into the buffer solution to obtain the 'non-specific binding value'.
Negative_regulation (blocking) of ryanodine receptor in reticulum
11) Confidence 0.05 Published 2006 Journal Yonsei Medical Journal Section Body Doc Link PMC2687630 Disease Relevance 0 Pain Relevance 0
As a result, the amount or the function of ryanodine receptor was supposed to be reduced.
Negative_regulation (reduced) of ryanodine receptor
12) Confidence 0.04 Published 2006 Journal Yonsei Medical Journal Section Body Doc Link PMC2687630 Disease Relevance 0.33 Pain Relevance 0
Other active ingredients in RYR include sterols (?
Negative_regulation (ingredients) of RYR
13) Confidence 0.04 Published 2008 Journal Chin Med Section Body Doc Link PMC2294127 Disease Relevance 0.05 Pain Relevance 0
‘Type1’ and ‘Type3’ inhibitions were clearly recognized, as well as the separateness of riluzole and nefazodone.
Negative_regulation (inhibitions) of Type1
14) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004914 Disease Relevance 0 Pain Relevance 0.11
Furthermore, morphine tolerance was reversed by intracerebroventricular administration of each of three different inhibitors of the CD38-cADPR-ryanodine receptor Ca(2+) signaling pathway.
Negative_regulation (inhibitors) of ryanodine receptor associated with tolerance, intracerebroventricular and morphine
15) Confidence 0.02 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 20551293 Disease Relevance 0.15 Pain Relevance 1.35
These inhibitors were the ADP-ribosylcyclase inhibitor nicotinamide, cADPR analog 8-bromo-cADPR, and a large dose of ryanodine (>50 muM) that blocks the ryanodine receptor.
Negative_regulation (blocks) of ryanodine receptor
16) Confidence 0.02 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 20551293 Disease Relevance 0.18 Pain Relevance 1.40
Change in body position from 30° head-up to 30° head-down resulted in significantly increased SV, GEDV and CVP, whereas SVVFloTrac, SVVPiCCO and PPV significantly decreased (Table 1 and Figure 1).
Negative_regulation (decreased) of SVVPiCCO in head
17) Confidence 0.01 Published 2008 Journal Crit Care Section Body Doc Link PMC2481481 Disease Relevance 0 Pain Relevance 0
Body positioning resulted in a significant increase in stroke volume; SVVFloTrac and SVVPiCCO decreased significantly.
Negative_regulation (decreased) of SVVPiCCO in Body associated with stroke
18) Confidence 0.01 Published 2008 Journal Crit Care Section Abstract Doc Link PMC2481481 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox